The investment will go toward improvements in the facility's safety and quality capacities, and it will be used to strengthen its R&D capabilities and productivity, Seqens said.

The investment will also enhance the company's involvement and commitment to U.S. operations, adding to Seqens' existing sales offices and a contract development and manufacturing operation already located in Newburyport, MA.

Furthermore, this investment follows SK Capital becoming a majority holder in Seqens through a merger with its portfolio company Wavelength Pharmaceuticals.

Wavelength's additional capabilities will enable the company to have greater reach and a more diverse portfolio of active pharmaceutical ingredients, as well as cytotoxic, steroidal, and high-potency products, Seqens said.

SK Capital Partners acquires Seqens
SK Capital Partners, a private investment firm, has acquired a majority shareholding in Seqens, which produces active ingredients, pharmaceutical intermediates,...